Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

NCT03719300 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Non-muscle Invasive Bladder Cancer (NMIBC)

Interventions

DRUG: inodiftagene vixteplasmid

Sponsor

Anchiano Therapeutics Israel Ltd.